Seizert Capital Partners LLC Has $6.24 Million Position in Incyte Co. (NASDAQ:INCY)

Seizert Capital Partners LLC raised its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 12.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 94,342 shares of the biopharmaceutical company's stock after buying an additional 10,438 shares during the quarter. Seizert Capital Partners LLC's holdings in Incyte were worth $6,236,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of INCY. MFA Wealth Advisors LLC bought a new position in Incyte during the second quarter valued at about $26,000. Innealta Capital LLC acquired a new position in shares of Incyte in the second quarter valued at $32,000. Itau Unibanco Holding S.A. bought a new position in Incyte in the second quarter worth $36,000. Deseret Mutual Benefit Administrators boosted its stake in Incyte by 37.1% during the second quarter. Deseret Mutual Benefit Administrators now owns 606 shares of the biopharmaceutical company's stock worth $37,000 after buying an additional 164 shares in the last quarter. Finally, Cromwell Holdings LLC increased its holdings in Incyte by 101.1% in the 3rd quarter. Cromwell Holdings LLC now owns 563 shares of the biopharmaceutical company's stock valued at $37,000 after buying an additional 283 shares during the period. 96.97% of the stock is owned by institutional investors.

Incyte Trading Down 2.4 %

NASDAQ INCY traded down $1.86 during trading hours on Friday, hitting $75.87. The company's stock had a trading volume of 3,842,709 shares, compared to its average volume of 2,015,147. The stock has a fifty day moving average of $68.99 and a 200 day moving average of $63.83. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. The firm has a market capitalization of $14.62 billion, a P/E ratio of 541.97, a PEG ratio of 8.75 and a beta of 0.71.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.12). Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the business earned $0.91 earnings per share. The firm's revenue for the quarter was up 23.8% on a year-over-year basis. Equities research analysts forecast that Incyte Co. will post 0.4 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Jonathan Elliott Dickinson sold 8,450 shares of Incyte stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $62.36, for a total transaction of $526,942.00. Following the transaction, the executive vice president now owns 36,390 shares in the company, valued at $2,269,280.40. The trade was a 18.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Barry P. Flannelly sold 3,680 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $79.68, for a total value of $293,222.40. Following the sale, the executive vice president now directly owns 58,042 shares of the company's stock, valued at approximately $4,624,786.56. The trade was a 5.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,702 shares of company stock valued at $856,166 in the last ninety days. 17.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. William Blair reiterated an "outperform" rating on shares of Incyte in a research report on Monday, September 9th. StockNews.com raised Incyte from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 31st. Morgan Stanley increased their target price on Incyte from $64.00 to $69.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 30th. Deutsche Bank Aktiengesellschaft boosted their price target on Incyte from $55.00 to $60.00 and gave the company a "hold" rating in a research note on Thursday, August 1st. Finally, Citigroup lifted their price objective on Incyte from $92.00 to $97.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $77.16.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.